Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions, various consumer healthcare environments, and eye health management settings in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-empowered retina-based auxiliary diagnosis product; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia and retinal detachment; and glaucoma, cataracts, ICVD and ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial hypertension retinopathy, and anemia SaMDs. The company also provides health risk assessment solutions to detect risk indicators, such as retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular diseases, and anemia to various healthcare providers, including health checkup centers, insurance companies, optometry centers, and pharmacies. In addition, it offers hardware devices comprising AI-FUNDUSCAMERA-P, AI-FUNDUSCAMERA-D, and AI-FUNDUSCAMERA-M fundus cameras. The company was incorporated in 2015 and is headquartered in Beijing, the People's Republic of China.